A new method development and validation for simultaneous estimation of ramipril and telmisartan by RP-HPLC method in combined dosage form
Department of Pharmaceutical Analysis, Mother Teresa Pharmacy College, Sathupally, Khammam, Telangana, India.
Research Article
GSC Biological and Pharmaceutical Sciences, 2024, 29(01), 296–301
Article DOI: 10.30574/gscbps.2024.29.1.0396
Publication history:
Received on 16 September 2024; revised on 23 October 2024; accepted on 26 October 2024
Abstract:
The present research work was development and validation of new RP-HPLC method for simultaneous estimation of Ramipril and Telmisartan in combined dosage form. In simultaneous RP-HPLC method development, Waters 2695 Separations Module with PDA Detector and column used is C8 SB ZORBAX (150 X 4.6mm) column with 3.5-micron particle size. Injection volume of 10 µL is injected and eluted with the mobile phase selected after optimization was Phosphate buffer and Acetonitrile in the ratio of 70:30 was found to be ideal. The optimized flow rate was at 1.0 mL/min. Detection was carried out at 230 nm. This system produced symmetric peak shape, good resolution and reasonable retention times of Ramipril and Telmisartan were found to be 2.275 and 4.261 minutes respectively. The Ramipril and Telmisartan showed linearity in the range of 20-60 µg/mL and 160-480 µg/mL respectively. The %RSD values for precision was found to be within the acceptable limit, which revealed that the developed method was precise. The developed method was found to be robust and the %RSD value for percentage recovery of Ramipril and Telmisartan was found to be within the acceptance criteria. The results indicate satisfactory accuracy of method for simultaneous estimation of the Ramipril and Telmisartan.
Keywords:
RP-HPLC; Ramipril; Telmisartan; UV Spectrum; HPLC water; Phosphate buffer
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
